Impact of Ministerial Decree 77/2022 from different stakeholders' perspectives: clinicians, pharmacists, patients, and industry [0.03%]
从不同利益相关者角度分析第77号部级法令（ ministerial decree No. 77/2022）的影响：临床医生、药剂师、患者及工业界的视角
Guido Attilio Condorelli,Martina Pipoli,Deborah Bonifacio et al.
Guido Attilio Condorelli et al.
Introduction: Assess the implications of Ministerial Decree (MD) 77/2022 in Italy, which decentralizes healthcare through proximity-based models, from the perspective of key actors involved, and discuss its relevance to s...
Comments on: Italian Medicines Agency's reform and time until pricing and reimbursement decisions: a time-to-event analysis [0.03%]
意大利药物机构改革及定价和报销决定所需时间的评论：一项事件发生时间分析
Giuseppe Traversa,Antonio Addis
Giuseppe Traversa
Author's reply to comments to: Italian Medicines Agency's reform and time until pricing and reimbursement decisions: a time-to-event analysis [0.03%]
致意大利药物管理局改革及药品定价和报销决定时间分析评论作者的回信
Gian Marco Raspolini,Bruno Federico,Mario Cesare Nurchis et al.
Gian Marco Raspolini et al.
Procedural activity and dynamics of the new Italian Scientific and Economic Committee (CSE): a one-year observational analysis [0.03%]
意大利新科学经济委员会(CSE)的程序活动和动态：一年观察分析
Entela Xoxi,Giulia Fagnocchi,Giovanni Callegaro et al.
Entela Xoxi et al.
Introduction: In January 2024, the Commissione Scientifica ed Economica (CSE) became the national body responsible for the integrated scientific and economic evaluation of medicines in Italy. This study provides the first...
Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma [0.03%]
CAR-T疗法在意大利医疗体系中的交付优化：滤泡性淋巴瘤的经济和组织学见解
Andrea Vitagliano,Marzia Bonfanti,Emanuele Angelucci et al.
Andrea Vitagliano et al.
Introduction: Follicular Lymphoma (FL) is the second most common lymphoid malignancy, with 20% of patients progressing within 24 months of first-line therapy. Chimeric antigen receptor T-cell (CAR-T) therapies have improv...
La riforma AIFA e i tempi di valutazione dei nuovi farmaci: l’impatto della nuova Commissione Scientifica ed Economica del Farmaco [0.03%]
意大利AIFA改革及新药评估周期的变化：新药物科学与经济委员会的影响
Benedetta Dal Canto,Vera Benedetto,Alma Martelli et al.
Benedetta Dal Canto et al.
Introduction:: Timely access to new medicines is a key dimension of health system performance. In Italy, pricing and reimbursement decisions are taken by the Italian Medicines Agency (AIFA). In 2024, a reform established ...
More and earlier data from AIFA: do they impact on the regional policies? Results from an exploratory analysis [0.03%]
来自AIFA更多的和更早的数据：它们会对地区政策产生影响吗？探索性分析结果
Riccardo Novaro,Mattia Altini,Francesca Futura Bernardi et al.
Riccardo Novaro et al.
Introduction: In Italy, drug prices and reimbursement are managed by the Italian Medicines Agency (AIFA), but regions actually enable patient access to medicines. Our aim is to provide evidence on (i) the current manageme...
Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy [0.03%]
意大利皮下注射和静脉注射免疫球蛋白治疗的最小成本分析
Chiara Bini,Matteo Scortichini,Silvia Ripoli et al.
Chiara Bini et al.
Introduction: Human immunoglobulins are the standard of care for patients with immunodeficiencies and represent a first-line treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to eval...
Raúl Ortiz de Lejarazu,Esther Redondo Margüello,Ángel Gil de Miguel et al.
Raúl Ortiz de Lejarazu et al.
Introduction: Influenza vaccines are formulated each year to prevent serious illness in at-risk individuals, including elderly people. Healthcare decision-making is mainly based on the economic evaluations (EEs) (i.e., co...
Ridiscussioni nel processo decisionale dell’Agenzia Italiana del Farmaco: una valutazione quantitativa di cause e implicazioni [0.03%]
意大利药物管理局决策过程中的重新讨论：原因及影响的定量评估
Michele Caimmi,Beatrice Canali,Anita Ciarlo et al.
Michele Caimmi et al.
Introduction:: Until 2024, Pricing and Reimbursement (P&R) requests for medicinal products in Italy were assessed by two separate bodies within AIFA: at first by the Technical Scientific Committee (CTS), then by the Prici...